GIM
SLNO

Greylin Investment Management’s Soleno Therapeutics SLNO Stock Holding History

Greylin Investment Management’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,453
Closed -$103K – 98
2021
Q1 		$103K Sell
5,453
-2,093
-28% -$67.5K 0.02% 89
2020
Q4 		$218K Sell
7,546
-1,400
-16% -$40.4K 0.05% 85
2020
Q3 		$337K Buy
+8,946
New +$261K 0.09% 67

Other funds holding SLNO

A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
OC
Oppenheimer & Co New York $9.37B AUM 36.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $179B AUM 65.34% 1-Year Est. Return

Greylin Investment Management's SLNO Position: Q2 2021 in Review

Greylin Investment Management sold out of Soleno Therapeutics (SLNO) in Q2 2021, closing a stake of 5,453 shares — an estimated $103K sold.

Greylin Investment Management first reported a position in SLNO in Q3 2020 and held it in 3 quarters. The position peaked at $337K in Q3 2020. 47 funds tracked by Wall St. Rank hold SLNO as of Q2 2021.

  • Greylin Investment Management reported no remaining Soleno Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Greylin Investment Management sold 5,453 Soleno Therapeutics shares in Q2 2021, an estimated $103K.
  • Greylin Investment Management first reported a position in Soleno Therapeutics in Q3 2020 and held it in 3 quarters.
  • Greylin Investment Management's Soleno Therapeutics position peaked at $337K in Q3 2020.
  • 47 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q2 2021.

Based on Greylin Investment Management's 13F filing for Q2 2021, filed 14 Jul 2021.